Get started
Author

Olaf Schoeman

Observed names: O Schoeman, O. Schoeman
OpenAlex ID: A5061557141
Cryopreservation of rat precision-cut liver and kidney slices by rapid freezing and vitrification
2006 · Inge A.M. de Graaf, Annelies L. Draaisma, et al. · Cryobiology · 61
Economic analysis of micafungin versus liposomal amphotericin B for treatment of candidaemia and invasive candidiasis in Germany
2008 · O. A. Cornely, M. Sidhu, et al. · Current Medical Research and Opinion · 40
Economic impact of 21-gene recurrence score testing on early-stage breast cancer in Ireland
2015 · Lillian Smyth, Geoff Watson, et al. · Breast Cancer Research and Treatment · 34
Cost-effectiveness analysis of micafungin versus caspofungin for treatment of systemic Candida infections in the UK
2009 · M. K. Sidhu, A. K. van Engen, et al. · Current Medical Research and Opinion · 26
Modified Delphi study of decision‐making around treatment sequencing in relapsing–remitting multiple sclerosis
2020 · M. A. Piena, O. Schoeman, et al. · European Journal of Neurology · 9
Cost-effectiveness Analysis of Rivaroxaban in the Secondary Prevention of Acute Coronary Syndromes in Sweden
2015 · Najida Begum, Stephanie Stephens, et al. · Cardiology and Therapy · 6
PDF
Desirability and acceptability of a treatment-sequencing model in relapsing-remitting multiple sclerosis: A health technology assessment perspective
2020 · Marjanne A. Piena, Olaf Schoeman, et al. · International Journal of Technology Assessment in Health Care · 5
Cost-Effectiveness of Nivolumab in Patients with Advanced or Metastatic Renal Cell Carcinoma in Portugal
2016 · K Verleger, AJ Almeida, et al. · Value in Health · 5
Pin13 Economic Analysis of Micafungin Versus Liposomal Amphotericin B for Treatment of Candidaemia and Invasive Candidiasis in Italy
2008 · P Viale, M Sidhu, et al. · Value in Health · 5
PDF
Pin27 Economic Analysis of Micafungin Versus Liposomal Amphotericin B Fortreatment of Candidaemia and Invasive Candidiasis in the United Kingdom
2008 · G Park, M Sidhu, et al. · Value in Health · 2
PDF
Pcv76 - Cost-effectiveness Analysis of Rivaroxaban in the Secondary Prevention of Acute Coronary Syndromes in Greece
2018 · P. Stafylas, M. Karaiskou, et al. · Value in Health · 1
A Comparison of Coverage and Reimbursement Decisions in Germany (AMNOG) and Scotland (SMC)
2013 · M. Charokopou, B. Heeg, et al. · Value in Health · 1
PDF
Health status impact of ciprofloxacin dry powder for inhalation in patients with non-cystic fibrosis bronchiectasis
2011 · Barbara Hampel, Olaf Schoeman, et al. · European Respiratory Journal · 1
Pcv18 Economic Evaluation of Oral Therapies for Pulmonary Arterial Hypertension
2006 · J Harriett, A Van Engen, et al. · Value in Health · 1
PDF
PCN41 Overall Complete Remission Rate (OCRR) and Complete Remission Rate (CR) of Standard of Care (SoC) in Relapsed/Refractory (R/R) Adult Acute Lymphoblastic Leukemia (aALL): A Meta-Analysis
2020 · O. Schoeman, C. Feng, et al. · Value in Health
PDF
Pcv40 - Budget Impact Analysis of Rivaroxaban in the Secondary Prevention of Acute Coronary Syndromes in Greece
2018 · P. Stafylas, M. Karaiskou, et al. · Value in Health
Predictors of German Amnog Decisions and GKV Rebate Negotiations: A Database Analysis
2014 · K. Verleger, O. Schoeman, et al. · Value in Health
A Comparison of Factors Influencing Reimbursement and Coverage Decisions in Scotland (Smc), The Netherlands (Nzi) and Germany (G-Ba)
2014 · M. Charokopou, C.J.M. Alleman, et al. · Value in Health
PHP36 – The Impact of Amnog on Drug Reimbursement in Germany
2013 · Bart Heeg, O. Schoeman, et al.
The Impact of Amnog on Drug Reimbursement in Germany
2013 · B. Heeg, O. Schoeman, et al. · Value in Health
PDF
Cost-Effectiveness Analysis of Rivaroxaban in Secondary Prevention of ACS in Sweden
2013 · N. Begum, B. Van Hout, et al. · Value in Health
Pnd14 Cost of Pseudomonas Aeruginosa in Cystic Fibrosis Patients in the United Kingdom
2009 · A Smalarz, B Harrow, et al. · Value in Health
PDF
Works count: 22
Citation count: 197
H-index: 6
I10-index: 4
Year
Topic
Type